key: cord-0710826-oxedaudq authors: Chalker, Victoria J.; Adler, Hugh; Ball, Robert; Naik, Falguni; Day, Jessica; Afshar, Baharak; Amin, Amit K. title: Fatal Co-infections with SARS-CoV-2 and Legionella pneumophila, England date: 2021-11-03 journal: Emerg Infect Dis DOI: 10.3201/eid2711.204121 sha: 86f7cdcf312f57f2c0bfda95dfa56d53cc060dee doc_id: 710826 cord_uid: oxedaudq Both Legionella pneumophila and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause pneumonia. L. pneumophila is acquired from water sources, sometimes in healthcare settings. We report 2 fatal cases of L. pneumophila and SARS-CoV-2 co-infection in England. Clinicians should be aware of possible L. pneumophila infections among SARS-CoV-2 patients. L egionnaires' disease, caused by Legionella bacteria, is a factor in community and healthcare acquired pneumonia. Legionella infection occurs from manmade water sources, including water aerosolized from cooling towers, spa pools, and water features, and from plumbing in hotels, workplaces, and healthcare facilities (1) , where patients can be more susceptible to infection (1) . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease (COVID-19), which also can cause pneumonia. Clinically differentiating Legionnaires' disease from COVID-19 requires laboratory diagnostics, such as urine antigen testing, PCR, and culture. The clinical focus on SARS-CoV-2 potentially causes underdiagnosis of L. pneumophila because clinicians might not suspect or investigate the bacterium, but co-infections have been reported. Documented co-infections in COVID-19 patients include human metapneumovirus (2), influenza (3), Chlamydia pneumoniae, Mycoplasma pneumoniae, non-COVID-19 coronavirus, enterovirus, rhinovirus, parainfluenza, and respiratory syncytial virus (4), and L. pneumophila in a case associated with a cruise ship (5) . Rapid identification of co-infections is essential for managing and treating severe COVID-19 cases (6) . We describe 2 cases of SARS-CoV-2 and L. pneumophila co-infection in patients admitted to hospitals in the United Kingdom. In February 2020, a female patient >65 years of age was admitted in Addisonian crisis. She was dis-Both Legionella pneumophila and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause pneumonia. L. pneumophila is acquired from water sources, sometimes in healthcare settings. We report 2 fatal cases of L. pneumophila and SARS-CoV-2 co-infection in England. Clinicians should be aware of possible L. pneumophila infections among SARS-CoV-2 patients. RESEARCH LETTERS charged to home but was readmitted to the same ward 8 days later with pneumonia. Her chest radiograph demonstrated minor bibasal opacity. The patient was prescribed amoxicillin/clavulanate and clarithromycin at admission for suspected bacterial infection; only clarithromycin would be effective against Legionella infection. No L. pneumophila nor SARS-CoV-2 testing was performed at admission and blood culture showed no growth. After initial clinical improvement, the patient's respiratory status deteriorated on day 10 and her chest radiograph showed extensive bilateral infiltrates. She tested positive for L. pneumophila by BinaxNOW Legionella Urinary antigen test (Alere, https://immuview.com) and for SARS-CoV-2 by PCR of nose and throat swab samples. L. pneumophila was confirmed by using Legionella Urinary Antigen EIA (Bartels, https://www.trinitybiotech.com) and Rapid Test Kit BinaxNOW Enzyme Immunoassay (EIA; Alere) on urine. No confirmatory lower respiratory samples were obtained. Despite antimicrobial drug and supportive treatment, the patient did not improve and was transitioned to palliative measures. She died 20 days after admission. We used culture to test water from all outlets on the ward; all were negative for L. pneumophila serogroup 1. We could not determine whether L. pneumophila and SARS-CoV-2 co-infection occurred in the community before hospital admission or in the hospital setting. Another co-infection occurred in a woman >80 years of age with a history of hypertension and chronic kidney disease who resided with her family in the community. She was admitted with dyspnea, hypoxia, and acute-on-chronic kidney injury in April 2020. Her chest radiograph demonstrated bilateral mid-and lowerzone consolidation, predominantly peripheral. The patient was prescribed amoxicillin/clavulanate and clarithromycin for suspected bacterial infection. The patient deteriorated over the subsequent 24 hours with progressive hypoxia despite maximal oxygen therapy. A nasal swab collected at admission tested positive for SARS-CoV-2 by PCR. Blood cultures collected at admission were negative. Per guidelines for testing for pneumonia, urine collected on day 2 after admission tested positive by BinaxNOW Legionella Urinary Antigen Test (Alere) and was confirmed with EIA as in the prior case; urinary pneumococcal antigen test was negative. No lower respiratory samples for confirmatory Legionella culture and typing were obtained. The treatment strategy was transitioned to palliative measures, and she died 5 days after admission. We assume this patient acquired both L. pneumophila and COVID-19 in the community, but she had no apparent epidemiologic risk for L. pneumophila, such as travel. Our study is limited by the low number of cases and the lack of lower respiratory specimens, which prevented confirmation and identification of L. pneumophila infection by PCR or culture. Nonetheless, Legionella testing of patients and water systems should not be neglected during the SARS-CoV-2 pandemic. Healthcare facilities and clinicians should continue to adhere to recommended protocols for L. pneumophila infection prevention and diagnosis. Even during the COVID-19 pandemic, patients are at risk for L. pneumophila infection in community and healthcare settings. Because periods of water system disuse can permit Legionella to grow and increase risk for infection (1) , pandemic measures, such as temporary closure and reopening of buildings, could increase risk for Legionella exposure. Healthcare facilities should follow national guidance for managing Legionella during the COVID-19 pandemic and consider publications from the European Society for Clinical Microbiology and Infectious Disease European Study Group for Legionella Infections (7). Hospital-acquired L. pneumophila cases and outbreaks can have higher fatality rates than community-acquired single cases (8). Recent data indicates bacterial co-infection in SARS-CoV-2 cases is uncommon in patients newly admitted to the hospital (9) . However, effects of L. pneumophila co-infection on COVID-19 mortality rates is not yet known. Large outbreaks might be missed because of reduced testing or less consideration for L. pneumophila infection in differential diagnosis. Clinicians should maintain Legionella testing and conduct patient investigations where clinically indicated during the pandemic. In conclusion, patients with SARS-CoV-2 might be at increased risk for other community-or healthcare-acquired infections. Clinicians should be aware of possible L. pneumophila infections among SARS-CoV-2 patients. Dr. Chalker is head of the Respiratory and Vaccine Preventable Bacteria Reference Laboratory in the United Kingdom Health Security Agency. Her research interests include molecular epidemiology and genomics of Legionella and other pathogens, clinical diagnostics, and outbreak analysis and control. The impact of the coexistence of Mycobacterium avium with Mycobacterium tuberculosis on the result of GeneXpert and MGIT susceptibility test Simultaneous diagnosis of tuberculous and non-tuberculous mycobacterial diseases: time for a better patient management Mixed infection of Mycobacterium abscessus subsp. abscessus and Mycobacterium tuberculosis in the lung Case report on pulmonary disease due to coinfection of Mycobacterium tuberculosis and Mycobacterium abscessus: difficulty in diagnosis Differential responses by human macrophages to infection with Mycobacterium tuberculosis and non-tuberculous mycobacteria Epidemiology and clinical management of Legionnaires' disease Co-infection with SARS-CoV-2 and human metapneumovirus Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area SARS-CoV-2 and Legionella co-infection in a person returning from a Nile Cruise Co-infections: potentially lethal and unexplored in COVID-19 Study Group for Legionella Infections Low rate of bacterial co-infection in patients with COVID-19 United Kingdom Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK; email: Vicki.chalker@phe.gov.uk Invasive Malaria Vector Anopheles stephensi Mosquitoes in Sudan Arwa Elaagip, Muzamil M. Abdel Hamid, Omnia Fateh Alrahman of Plasmodium vivax and P. falciparum. Their native range centers on the Indian subcontinent, from which they are increasingly expanding their geographic distribution (1) . Recent establishment in Ethiopia (2) and Djibouti (3) is especially worrying. We document the emergence of An. stephensi mosquitoes in Sudan.Among study sites in a study originally investigating insecticide resistance in the dominant malaria vector in Sudan, Anopheles arabiensis mosquitoes, we selected 12 sites in the eastern half of the country to represent the different ecologic zones (Appendix Figure 1 , https://wwwnc.cdc.gov/ EID/article/27/11/21-0400-App1.pdf). We collected Anopheles spp. larvae from all sites in 2016 and from most again in late 2017 or early 2018 (Appendix Table 1 ). We reared the larvae to adults, checked them morphologically, and initially identified the species as An. gambiae s.l. We extracted DNA from a subset for molecular identification of the species by PCR (3). Of these, 149 DNA samples failed to amplify when we used the standard protocol for identification of the An. gambiae complex, and we investigated them further. We performed mitochondrial cytochrome oxidase 1 amplification and sequencing by using the universal primers C1-J-2183 and TL2-N-3014 on the first batch (4); to provide conformity with other studies in East Africa, we used Folmer primers LCO1490 and HCO2198 on a second batch (4) . To confirm species identity, we performed BLAST (https://blast.ncbi.nlm. nih.gov/Blast.cgi) searches. We supplemented sequences generated for the mosquitoes from Sudan by using the Folmer primers with sequences from other studies downloaded from GenBank, assembled them by using Clustal within MEGAX (5) , and displayed the results as a maximum-likelihood tree with 1,000 bootstraps.Sequence analysis demonstrated that many of the samples failing diagnostic PCR were not An. gambiae s.l. mosquitoes; most samples identified by BLAST were An. stephensi mosquitoes (Appendix Table 1 ). The relative frequencies of An. stephensi mosquito detection were similarly high (>40%) among those Anopheles stephensi mosquitoes are urban malaria vectors in Asia that have recently invaded the Horn of Africa. We detected emergence of An. stephensi mosquitoes in 2 noncontiguous states of eastern Sudan. Results of mitochondrial DNA sequencing suggest the possibility of distinct invasions, potentially from a neighboring country.